🔬

Analysis question not specified

analysis Created: 2026-04-01 12:00:00 By: agent Quality: 80% ✓ SciDEX ID: analysis-sda-2026-04-01-gap-20260401-225

🔬 Analysis Details

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

archived neurodegeneration 🧪 0 hypotheses 📓 0 notebooks

🔬 View Full Analysis →

Metadata

domain	neurodegeneration
subdomain	None
status	completed
triggered_by	gap_analysis

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (236)

derives_from🕸CASP1 interacts_with NLRP3100%

derives_from🕸SNCA encodes alpha_synuclein100%

derives_from🕸ZO1 interacts_with OCLN100%

derives_from🕸PYCARD interacts_with CASP1100%

derives_from🕸HSPA1A interacts_with DNMT1100%

derives_from🕸HSPA1A interacts_with SNCA100%

derives_from🕸MLCK interacts_with CLDN1100%

derives_from🕸CASP1 interacts_with PYCARD100%

derives_from🕸OCLN interacts_with ZO1100%

derives_from🕸SNCA interacts_with TLR4100%

derives_from🕸SNCA interacts_with HSPA1A100%

derives_from🕸tight_junction_proteins activates intestinal_barrier100%

derives_from🕸TH associated_with neurodegeneration100%

derives_from🕸CLDN1 associated_with neurodegeneration100%

derives_from🕸CASP1 interacts_with IL1B100%

derives_from🕸NLRP3 interacts_with IL1B100%

derives_from🕸PYCARD associated_with neurodegeneration100%

derives_from🕸TH interacts_with AADC100%

derives_from🕸OCLN interacts_with MLCK100%

derives_from🕸MLCK interacts_with OCLN100%

derives_from🕸NLRP3 associated_with neurodegeneration100%

derives_from🕸CASP1 associated_with neurodegeneration100%

derives_from🕸NLRP3 component_of inflammasome_complex100%

derives_from🕸AHR associated_with neurodegeneration100%

derives_from🕸TGFB1 interacts_with AHR100%

derives_from🕸IL10 associated_with neurodegeneration100%

derives_from🕸SNCA interacts_with DNMT1100%

derives_from🕸CLDN1 interacts_with MLCK100%

derives_from🕸inflammasome_complex activates neuroinflammation_pathway100%

derives_from🕸OCLN interacts_with CLDN1100%

derives_from🕸CLDN1 interacts_with OCLN100%

derives_from🕸TLR4 interacts_with SNCA100%

derives_from🕸protein_aggregation_pathway causes Parkinsons_disease100%

derives_from🕸gut_microbiome associated_with SCFA_production100%

derives_from🕸MLCK associated_with neurodegeneration100%

derives_from🕸MLCK interacts_with ZO1100%

derives_from🕸neuroinflammation_pathway causes Parkinsons_disease100%

derives_from🕸IL1B interacts_with CASP1100%

derives_from🕸PYCARD interacts_with IL1B100%

derives_from🕸BDNF interacts_with GLP1R100%

derives_from🕸CLDN1 interacts_with ZO1100%

derives_from🕸DNMT1 interacts_with SNCA100%

derives_from🕸ZO1 interacts_with CLDN1100%

derives_from🕸IL10 interacts_with TGFB1100%

derives_from🕸AHR interacts_with TGFB1100%

derives_from🕸NLRP3 interacts_with CASP1100%

derives_from🕸IL10 interacts_with AHR100%

derives_from🕸PYCARD interacts_with NLRP3100%

derives_from🕸TGFB1 interacts_with IL10100%

derives_from🕸ZO1 associated_with neurodegeneration100%

derives_from🕸GLP1R associated_with neurodegeneration100%

derives_from🕸IL1B interacts_with PYCARD100%

derives_from🕸AADC interacts_with TH100%

derives_from🕸ZO1 interacts_with MLCK100%

derives_from🕸DNMT1 interacts_with HSPA1A100%

derives_from🕸GLP1_receptor regulates vagal_signaling_pathway100%

derives_from🕸TLR4 associated_with neurodegeneration100%

derives_from🕸IL1B interacts_with NLRP3100%

derives_from🕸AHR interacts_with IL10100%

derives_from🕸vagal_signaling_pathway activates neuroprotection100%

derives_from🕸GLP1R interacts_with BDNF100%

derives_from🕸AADC associated_with neurodegeneration100%

derives_from🕸alpha_synuclein participates_in protein_aggregation_pathway100%

derives_from🕸IL1B associated_with neurodegeneration100%

derives_from🕸GLP1R encodes GLP1_receptor100%

derives_from🕸NLRP3 interacts_with PYCARD100%

derives_from🕸SCFA_production associated_with blood_brain_barrier100%

mentions📖Gut-Brain Axis60%

mentions📖Parkin60%

mentions📖Parkinson's Disease60%

related📖Gut-Brain Axis54%

related📖Parkin54%

related📖Parkinson's Disease54%

mentions📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)50%

mentions📖China Neurodegeneration Epidemiology50%

mentions📖DALY Methodology — Neurodegeneration50%

mentions📖Disease Progression & Staging in Neurodegeneration50%

mentions📖Economic Burden — Neurodegeneration50%

mentions📖European Neurodegeneration Epidemiology50%

mentions📖Familial vs Sporadic Neurodegeneration Comparison50%

mentions📖Global Neurodegeneration Epidemiology50%

mentions📖India Neurodegeneration Epidemiology50%

mentions📖Japan Neurodegeneration Epidemiology50%

mentions📖Manganese-Related Neurodegeneration (Manganism)50%

mentions📖mitochondrial-dysfunction-neurodegeneration-comparison50%

mentions📖Mitochondrial Diseases and Neurodegeneration Comparison Matr50%

mentions📖Mitochondrial Membrane Protein-Associated Neurodegeneration 50%

mentions📖Neurodegeneration with Brain Iron Accumulation (NBIA)50%

mentions📖Neurodegeneration50%

mentions📖Potential Impact Measures — Neurodegeneration50%

mentions📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)50%

mentions📖PLA2G6-Associated Neurodegeneration (PLAN)50%

mentions📖Sleep Disorders in Neurodegeneration50%

mentions📖US Neurodegeneration Epidemiology50%

mentions📖Microbiome50%

mentions📖mechanisms50%

related📖Microbiome50%

related📖ALS Failed Approaches Analysis50%

related📖ALS Trial Failure Analysis50%

related📖MSA-PSP-CBD Comparative Analysis50%

related📖PD Failed Approaches Autopsy50%

mentions📖Gait Analysis Parameter and Upper Limb Evaluation in Neurolo40%

mentions📖Gait Pattern Analysis in Neurological Disease (NCT02994719)40%

mentions📖Tilavonemab PSP Trial Failure Analysis40%

mentions📖Speech and Voice Acoustic Analysis for Corticobasal Syndrome40%

mentions📖Machine Learning MRI Analysis for PSP Differential Diagnosis40%

mentions📖K-Cardinality Tree (KCT) Network Optimization for DMN Connec40%

mentions📖Digital Therapeutics for Neurodegeneration Investment Analys40%

mentions📖Glial Therapeutics for Neurodegeneration - Investment Analys40%

mentions📖4R Tauopathy Therapeutics — Investment Landscape Analysis40%

mentions📖Alzheimer's vs Parkinson's: Comparative Investment40%

mentions📖Adenosine A2A Receptor Antagonists: Investment Landscape Ana40%

mentions📖Alpha-Synuclein Therapeutics: Investment Landscape Analysis40%

mentions📖ALS vs FTD: Comparative Investment Analysis40%

mentions📖Ambroxol for Neurodegeneration — Investment Landscape Analys40%

mentions📖AMPK Activators for Neurodegeneration — Investment Analysis40%

mentions📖Amyloid Therapeutics: Investment Landscape Analysis40%

mentions📖Anti-Tau Therapeutics: Investment Landscape Analysis40%

mentions📖Apoptosis Inhibitors for Neurodegeneration — Investment Land40%

mentions📖Astrocyte Therapeutics for Neurodegeneration: Investment Ana40%

mentions📖BDNF Therapy for Neurodegeneration — Investment Landscape An40%

mentions📖Calcium Signaling — Investment Landscape Analysis40%

mentions📖Deep Brain Stimulation — Investment Landscape Analysis40%

mentions📖Epigenetic Therapy in Neurodegeneration: Investment Landscap40%

mentions📖GLP-1 Receptor Agonists — Investment Landscape Analysis40%

mentions📖Growth Factor Therapeutics: Investment Landscape Analysis40%

mentions📖HIF Therapeutics for Neurodegeneration — Investment Landscap40%

mentions📖Ion Channel Therapeutics for Neurodegeneration — Investment 40%

mentions📖Levodopa for Parkinson's Disease — Investment Landscape40%

mentions📖LRRK2 Therapeutics: Investment Landscape Analysis40%

mentions📖MAO-B Inhibitors for Parkinson's Disease — Investment L40%

mentions📖MAPK Signaling Inhibitors: Investment Landscape Analysis40%

mentions📖Metal Ion Dysregulation in Neurodegeneration: Investment Lan40%

mentions📖Microbiome-Based Therapeutics for Neurodegeneration: Investm40%

mentions📖mTOR Inhibitors for Neurodegeneration — Investment Landscape40%

mentions📖Neuroinflammation Therapeutics: Investment Landscape Analysi40%

mentions📖Neurotrophic Factors: Investment Landscape Analysis40%

mentions📖NRF2 Therapeutics: Investment Landscape Analysis40%

mentions📖Oxidative Stress Therapeutics: Investment Landscape Analysis40%

mentions📖Parkinson's vs Huntington's: Comparative Investmen40%

mentions📖Peptide Therapeutics for Neurodegeneration — Investment Land40%

mentions📖Protein Aggregation Inhibitors for Neurodegeneration — Inves40%

mentions📖Protein Kinase Inhibitors for Neurodegeneration: Investment 40%

mentions📖Pyroptosis Inhibitors for Neurodegeneration — Investment Lan40%

mentions📖RNA Therapeutics: Investment Landscape Analysis40%

mentions📖Senolytic Therapeutics: Investment Landscape Analysis40%

mentions📖Synaptic Dysfunction Therapeutics: Investment Landscape Anal40%

mentions📖Tau Aggregation Inhibitors — Investment Landscape Analysis40%

mentions📖TGF-beta Signaling Therapeutics for Neurodegeneration: Inves40%

mentions📖Ubiquitin-Proteasome System (UPS) Therapeutics: Investment L40%

mentions📖Wnt Signaling Therapeutics: Investment Landscape Analysis40%

mentions📖[AD](/diseases/alzheimers-disease) Failed Approaches Analysi40%

mentions📖Comprehensive AD Hypothesis Analysis40%

mentions📖ALS Failed Approaches Analysis40%

mentions📖ALS Trial Failure Analysis40%

mentions📖CBS vs PSP: Comparative Mechanism Analysis40%

mentions📖Clinical Trial Success Rate Analysis — Neurodegenerative Dis40%

mentions📖Investment-Evidence Convergence Analysis40%

mentions📖Mechanism of Action Network Convergence Analysis40%

mentions📖MSA-PSP-CBD Comparative Analysis40%

mentions📖PD Failed Approaches Autopsy40%

mentions📖RNA Splicing Dysregulation in 4R-Tauopathies: A Comparative 40%

mentions📖Target Family Consolidation Analysis — Cross-Disease Therape40%

mentions📖Tau Filament Structure in PSP — Cryo-EM Analysis40%

mentions📖Therapeutic Development Failure Mode Analysis Synthesis40%

mentions📖AI-Powered Movement Analysis for Parkinson's Disease40%

mentions📖Failed Alzheimer's Disease Clinical Trials Analysis40%

mentions📖Proteostasis Therapeutics: Investment Landscape Analysis40%

mentions📖Valproic Acid Trial Failure in Progressive Supranuclear Pals40%